MD Anderson
In Brief This Week: MD Anderson, Genascence, Seattle Children's Hospital, Abeona, Mount Sinai
News items for the week of Nov. 11, 2024.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
MD Anderson, Summit Therapeutics to Jointly Study Ivonescimab
The partners inked a five-year deal to study the PD-1/VEGF bispecific antibody across multiple tumor types, including in biomarker-defined indications.
Although the PETRA trial didn't test saruparib against marketed PARP inhibitors, researchers see promising signs that the agent has a better toxicity profile.
Replay, MD Anderson Venture Syena Bets on NK Cells to Bring TCR Therapy to Solid, Blood Cancers
Premium
After launching the first therapy, NY-ESO-1 TCR/IL-15 NK, in a multiple myeloma trial earlier this month, Syena is exploring the approach in new targets and tumor types.
May 18, 2023